<DOC>
	<DOCNO>NCT00247143</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy high dos lopinavir/ritonavir , combination anti-HIV medication administer either capsule liquid formulation , among patient full viral suppression despite treatment 3 class HIV medication , least 2 prior course treatment HIV protease inhibitor . In addition , pharmacokinetics active agent , lopinavir ritonavir measure follow administration liquid capsule formulation compare .</brief_summary>
	<brief_title>High Dose Ritonavir/Lopinavir Liquid Formulation Salvage Therapy Protease Inhibitor Resistant HIV Disease</brief_title>
	<detailed_description>This study safety , efficacy , tolerability study high dose kaletra patient fail multiple antiretroviral regimen , include prior treatment 3 class antiretroviral drug ( nucleoside/nucleotide analogue , non-nucleoside analogue , least one protease inhibitor base ARV regimen ) , conjunction optimize background therapy . Patients initially treat high dose kaletra capsule optimize background therapy 4 week switch equivalent dos high dose kaletra liquid formulation total duration therapy 24 week . The primary endpoint study average HIV RNA change baseline 24 week ( HIV RNA AACUMB ) . Secondary endpoint include proportion achieve HIV RNA &lt; 50 HIV RNA &lt; 400 copies/mL 24 week . Changes CD4 baseline , change LPV fold change phenotypic resistance testing , change fast metabolic parameter , assessment safety week 24 base upon hematology , chemistry , liver function , lipid level , proportion patient report adverse event proportion patient SAEs , demonstration bioequivalence 12 hour pharmacokinetic measurement .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1 . Signed informed consent prior trial participation . 2 . HIV1 infect male female least 18 year age . 3 . Weight &gt; 60 kg &lt; 100 kg 4 . Acceptable laboratory screen value define exclusion criterion . 5 . Three class ARV experience , include current PI regimen least 12 week , least one PI base regimen least 12 week , treatment least one NNRTI least 2 nucleoside agent . 6 . Screening Virologic Phenotype demonstrate lopinavir phenotypic fold resistance 10 80 ( patient Virologic Phenotype within 8 week study screen may use qualify lopinavir phenotypic fold resistance ) . 7 . HIV1 viral load 1000 copies/mL screening . 8 . Acceptable screen laboratory value indicate adequate baseline organ function . Laboratory value consider acceptable follow apply : Total Cholesterol ≤ DAIDS Grade 3 Total Triglycerides ≤ DAIDS Grade 3 ALT AST ≤DAIDS Grade 3 ) . Any Grade GGT acceptable . Any Grade CK acceptable long concurrent myopathy . All laboratory test value ≤DAIDS Grade 2 . 9 . Willingness discontinue treatment NNRTIs throughout 48 week study participation ( prior current treatment enfuvirtide permit ) . 10 . Acceptable medical history , assess investigator , unremarkable chest Xray ECG within 1 year study participation . 11 . Willingness abstain ingest substance study may alter plasma study drug level interaction cytochrome P450 system ( list inform consent risk lopinavir/ritonavir ) . 12 . A prior AIDSdefining event acceptable long resolve patient stable therapy least 12 week . 1 . ARV medication naïve . 2 . Patients recent drug holiday , define ARV medication least 7 consecutive day within last 28 day 3 . Female patient childbearing potential : positive serum pregnancy test screening study , breast feeding , plan become pregnant , willing use barrier method contraception , require ethinyl estradiol administration . 4 . Prior highdose LPV/RTV therapy ( high recommend dos package insert ) . 5 . Active diarrhea control antidiarrheal medication ( exceed 3 bowel movements/day ) , malabsorption , GI intolerance lopinavir/ritonavir 6 . Use investigational medication within 30 day study entry trial . 7 . Are receive medication contraindicate , result significant drugdrug interaction , LPV and/or RTV ( include , limited triazolam , astemizole , ergot medication , cisapride , midazolam , bepridils , rifampin ) . 8 . Use immunomodulatory drug within 30 day study entry trial ( e.g . interferon , cyclosporin , hydroxyurea , interleukin 2 ) . 9 . Active malignancy require chemotherapy radiation . 10 . Inability adhere requirement protocol , include active substance abuse assess investigator . 11 . In opinion investigator , likely survival le 6 month underlying disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Antiretroviral Agents</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>